No connection

Search Results

NOTV vs SILO

NOTV
Inotiv, Inc.
BEARISH
Price
$0.24
Market Cap
$8.4M
Sector
Healthcare
AI Confidence
95%
SILO
Silo Pharma, Inc.
BEARISH
Price
$0.52
Market Cap
$8.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
NOTV
--
SILO
--
Forward P/E
NOTV
-4.9
SILO
-0.74
P/B Ratio
NOTV
0.08
SILO
1.09
P/S Ratio
NOTV
0.02
SILO
116.19
EV/EBITDA
NOTV
26.68
SILO
-0.1

Profitability

Gross Margin
NOTV
23.49%
SILO
38.57%
Operating Margin
NOTV
-13.36%
SILO
-4363.27%
Profit Margin
NOTV
-13.5%
SILO
0.0%
ROE
NOTV
-49.76%
SILO
-74.56%
ROA
NOTV
-3.14%
SILO
-35.63%

Growth

Revenue Growth
NOTV
0.8%
SILO
0.0%
Earnings Growth
NOTV
--
SILO
--

Financial Health

Debt/Equity
NOTV
4.37
SILO
--
Current Ratio
NOTV
0.3
SILO
11.36
Quick Ratio
NOTV
0.17
SILO
10.55

Dividends

Dividend Yield
NOTV
--
SILO
--
Payout Ratio
NOTV
0.0%
SILO
0.0%

AI Verdict

NOTV BEARISH

NOTV exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.30 and a Quick Ratio of 0.17, suggesting it cannot meet its short-term obligations. High leverage (Debt/Equity of 4.37) combined with stagnant revenue growth (0.80%) and consistent earnings misses creates a high risk of insolvency. The catastrophic 5-year price decline of 98.8% and bearish insider activity further confirm a negative outlook.

Strengths
Positive Gross Margin (23.49%)
Extremely low Price-to-Sales ratio (0.02)
Extremely low Price-to-Book ratio (0.08)
Risks
Severe liquidity risk (Current Ratio 0.30)
Excessive leverage (Debt/Equity 4.37)
Consistent failure to meet earnings estimates (0/4 beats)
SILO BEARISH

SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.

Strengths
Strong short-term liquidity (Current Ratio: 11.36)
Price/Book ratio near 1.09 suggests the stock is trading close to its accounting value
Recent short-term price momentum (+60.9% in 1 month)
Risks
Extreme fundamental weakness (Piotroski F-Score 0/9)
Zero revenue growth (YoY and Q/Q)
Massive operating losses (-4363.27% operating margin)

Compare Another Pair

NOTV vs SILO: Head-to-Head Comparison

This page compares Inotiv, Inc. (NOTV) and Silo Pharma, Inc. (SILO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile